Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Shattuck Labs, Inc. STTK NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
55/100
4/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$10.50
+54.9%

Shattuck Labs, Inc. (STTK) is a Biotechnology company in the Healthcare sector, currently trading at $6.78. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Analyst consensus target is STTK = $11 (+54.9% upside).

Valuation: STTK trades at a trailing Price-to-Earnings (P/E) of -15.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.97.

Financials: revenue is $1M, +105.6%/yr average growth. Net income is $49M (loss), growing at +21.1%/yr. Net profit margin is -4880.9% (negative). Gross margin is -268.8% (+148.8 pp trend).

Balance sheet: total debt is $2M against $82M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 11.7 (strong liquidity). Debt-to-assets is 1.7%. Total assets: $91M.

Analyst outlook: 7 / 9 analysts rate STTK as buy (78%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 74/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 15/100 (Fail), Future 85/100 (Pass), Income 10/100 (Fail).

$10.50
▲ 54.87% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Shattuck Labs, Inc., the average price target is $10.50, with a high forecast of $15.00, and a low forecast of $6.00.
Highest Price Target
$15.00
Average Price Target
$10.50
Lowest Price Target
$6.00

STTK SharesGrow Score Overview

64/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 74/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 15/100
Gross margin is + market cap
FUTURE 85/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — STTK

✓
VALUE Pass
74/100
STTK trades at a trailing Price-to-Earnings (P/E) of -15.4 (S&P 500 average ~25). Forward PEG 1.97 — overvalued. Analyst consensus target is $11, implying +62.2% from the current price $7. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
100/100
STTK: +105.6%/yr revenue is, +21.1%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet STTK: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 11.7 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
15/100
STTK: Gross margin is -268.8% (+148.8 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 15/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
85/100
Analyst outlook: 7 / 9 analysts rate STTK as buy (78%). Analyst consensus target is $11 (+62.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
STTK: Net profit margin is -4880.9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.692-6.81
Volume315.86K
Avg Volume (30D)630.82K
Market Cap$324.78M
Beta (1Y)1.29
Share Statistics
EPS (TTM)-0.70
Shares Outstanding$69.58M
IPO Date2020-10-09
Employees44
CEOTaylor H. Schreiber
Financial Highlights & Ratios
Revenue (TTM)$1M
Gross Profit$-2.69M
EBITDA$-47.84M
Net Income$-48.81M
Operating Income$-51.51M
Total Cash$78.07M
Total Debt$1.58M
Net Debt$-52.61M
Total Assets$91.03M
Price / Earnings (P/E)-9.7
Price / Sales (P/S)324.78
Analyst Forecast
1Y Price Target$10.50
Target High$15.00
Target Low$6.00
Upside+54.9%
Rating ConsensusBuy
Analysts Covering9
Buy 78% Hold 22% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS82024L1035

Price Chart

Track all markets on TradingView
STTK
Shattuck Labs, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.69 52WK RANGE 6.81

People Also View

KYMR
KYMR
Kymera Therapeutics, Inc.
$89.87
+1.51%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 NRIX
NRIX
Nurix Therapeutics, Inc.
$16.30
+2.45%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 FHTX
FHTX
Foghorn Therapeutics Inc.
$4.85
+3.41%
 PRLD
PRLD
Prelude Therapeutics Incorporated
$4.40
+0.69%
 CCCC
CCCC
C4 Therapeutics, Inc.
$2.76
+0.91%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message